Active	Status	Sponsor type	Region	Phase	Filter
27 Active 10 Inactive 37 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Liu, Yi
NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease	Recruiting	3	225	RoW	Belimumab	GlaxoSmithKline, ICON plc	Bronchial Diseases	08/28	01/30
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.	Recruiting	2/3	240	Europe, Canada, Japan, US, RoW	EFG PH20 SC, PBO	argenx, argenx BV	Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome	12/26	02/27
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE	Recruiting	2/3	300	Europe, Japan, US, RoW	Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo	GlaxoSmithKline	Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic	07/27	07/27
NCT04324879: A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)	Recruiting	2	80	RoW	TQ-B3525	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Relapsed / Refractory Follicular Lymphoma	12/22	12/22
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE) Oct 2024 - Dec 2024 : Data for SLE Jul 2024 - Sep 2024 : Data for CLE	Completed	2	456	Europe, Japan, US, RoW	Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Systemic Lupus Erythematosus	11/24	11/24
TRIPHY, NCT06480890: Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients	Recruiting	N/A	359	RoW		Chiesi Farmaceutici S.p.A.	Chronic Obstructive Pulmonary Disease	10/25	10/25
Cai, Shanjun
NCT05439629: Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration	Active, not recruiting	3	488	RoW	BAT5906 injection, Lucentis	Bio-Thera Solutions	Neovascular (Wet) Age-related Macular Degeneration	04/24	06/25
Ren, Xu
No trials found